OUR PORTFOLIO

OUR COMPANIES REDEFINE THE THERAPEUTICS OF TOMORROW

carm600_edited.png
  • LinkedIn - Grey Circle

CARMINE THERAPEUTICS

Carmine Therapeutics is an EVX Ventures company pioneering a powerful new class of genetic medicines based on engineered red blood cells extracellular vesicles (RBCEVs), founded in 2019 by Esco Ventures and Professors Harvey Lodish, Minh Le and Jiahai Shi.

  • LinkedIn - Grey Circle

PAIRX BIO

PairX Bio Pte Ltd is developing next generation cancer immunotherapies targeting shared tumor-associated antigens derived from aberrantly spliced proteins. The foundational technology was developed at Duke-NUS Medical School in Prof. David Epstein’s lab.

  • LinkedIn - Grey Circle
  • Twitter - Grey Circle
  • Facebook - Grey Circle
  • G+ - Grey Circle

HUMMINGBIRD BIOSCIENCE

Hummingbird Bioscience focuses on the discovery and early development of oncology drugs, from pre-clinical target validation to proof-of-concept (Phase II Clinical Trials).

logo.png
  • LinkedIn - Grey Circle

ALTRUBIO

AltruBio is a clinical-stage biotech company focused on developing novel antibody therapeutics based on unique insights into T cell activation, to treat immunological diseases with high unmet medical needs, such as steroid-refractory acute GvHD.

VENTURES X_EVX_INTL LOGO-FINAL-BLACK.png

EVX07

To be disclosed

VENTURES X_EVX_INTL LOGO-FINAL-BLACK.png

EVX08

To be disclosed